argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone329-310-3400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$44.74 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
argenx (NASDAQ:ARGX) Frequently Asked Questions
What is argenx's stock symbol?
argenx trades on the NASDAQ under the ticker symbol "ARGX."
What price target have analysts set for ARGX?
12 analysts have issued 12 month price targets for argenx's shares. Their predictions range from $110.00 to $161.00. On average, they anticipate argenx's share price to reach $144.80 in the next twelve months. This suggests a possible upside of 9.7% from the stock's current price. View Analyst Price Targets for argenx.
What is the consensus analysts' recommendation for argenx?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for argenx.
What are Wall Street analysts saying about argenx stock?
Here are some recent quotes from research analysts about argenx stock:
- 1. According to Zacks Investment Research, "argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. " (3/5/2019)
- 2. Stifel Nicolaus analysts commented, "We believe ARGX’s collaboration agreement with Halozyme Therapeutics (HALO, $16.12, Not Covered) is an important development for the company and the FcRn competitive landscape. Having already validated a small volume subcutaneous dose of efgartigimod, ARGX remains in the lead on this initiative, and we believe the exclusive license signed with HALO for its validated ENHANZE drug delivery technology not only could offer even more dosing convenience for patients, but, based on our understanding from communicating with ARGX, it also prevents other FcRn competitors from collaborating with HALO on a subcutaneous dosing strategy." (2/4/2019)
Has argenx been receiving favorable news coverage?
Media headlines about ARGX stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. argenx earned a news impact score of -1.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the next few days.
Are investors shorting argenx?
argenx saw a drop in short interest during the month of February. As of February 28th, there was short interest totalling 697,670 shares, a drop of 30.8% from the February 15th total of 1,007,641 shares. Based on an average trading volume of 215,501 shares, the days-to-cover ratio is currently 3.2 days. Approximately 1.9% of the company's stock are sold short. View argenx's Current Options Chain.
Who are some of argenx's key competitors?
Some companies that are related to argenx include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI) and Aerie Pharmaceuticals (AERI).
What other stocks do shareholders of argenx own?
Who are argenx's key executives?
argenx's management team includes the folowing people:
- Mr. Tim Van Hauwermeiren, CEO & Exec. Director (Age 47)
- Mr. Eric Castaldi, Chief Financial Officer (Age 55)
- Prof. Hans de Haard, Chief Scientific Officer (Age 59)
- Mr. Dirk Marcel Leon Beeusaert, Gen. Counsel (Age 55)
- Dr. Torsten Dreier, Chief Devel. Officer (Age 55)
When did argenx IPO?
(ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are argenx's major shareholders?
argenx's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (10.84%), BB Biotech AG (2.75%), venBio Select Advisor LLC (2.67%), Orbimed Advisors LLC (2.01%), Jennison Associates LLC (1.58%) and Oberweis Asset Management Inc. (0.89%).
Which major investors are selling argenx stock?
ARGX stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Jane Street Group LLC, Orbimed Advisors LLC, Millennium Management LLC, Sphera Funds Management LTD., Barclays PLC, Weiss Multi Strategy Advisers LLC and Connor Clark & Lunn Investment Management Ltd..
Which major investors are buying argenx stock?
ARGX stock was bought by a variety of institutional investors in the last quarter, including Oberweis Asset Management Inc., BlackRock Inc., Lord Abbett & CO. LLC, BB Biotech AG, Partner Fund Management L.P., venBio Select Advisor LLC, Artal Group S.A. and Fosun International Ltd.
How do I buy shares of argenx?
Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is argenx's stock price today?
One share of ARGX stock can currently be purchased for approximately $131.95.
How big of a company is argenx?
argenx has a market capitalization of $4.24 billion and generates $44.74 million in revenue each year. The company earns $-31,730,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.
What is argenx's official website?
How can I contact argenx?
argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected]
MarketBeat Community Rating for argenx (NASDAQ ARGX)
MarketBeat's community ratings are surveys of what our community members think about argenx and other stocks. Vote "Outperform" if you believe ARGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
